Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.

Medical oncology (Northwood, London, England) - 1 Jan 2008

Lim Ken-Hong, Huang Ming-Jer, Chen Li-Tzong, Wang Tsang-En, Liu Chien-Liang, Chang Cheng-Shyong, Liu Mei-Chin, Hsieh Reuy-Kuen, Tzen Chin-Yuan

Abstract excerpt

Most gastrointestinal stromal tumors (GISTs) are associated with activating kinase mutation in KIT or platelet-derived growth factor receptor alpha (PDGFRA) gene, and imatinib has revolutionized the care of advanced GISTs. However, most patients gradually developed resistance to imatinib. We intend to identify the secondary kinase mutations in imatinib-resistant GISTs and to study the relationship between...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Share to Receptor, Platelet-Derived Growth Factor alpha

Source

Identifiers

PMID: 18488160
DOI: 10.1007/s12032-007-9014-2

Genes

KIT
PDGFRA

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.PMID 18488160Read ↗

Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors.Semantic proximity Read ↗

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.Semantic proximity Read ↗

Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).Semantic proximity Read ↗

Clinical impact of primary and secondary KIT mutations on the efficacy of molecular-targeted therapies in gastrointestinal stromal tumors.Semantic proximity Read ↗

Secondary mutations in the kinase domain of the <i> KIT</i> gene are predominant in imatinib‐resistant gastrointestinal stromal tumorSemantic proximity Read ↗

KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.Semantic proximity Read ↗

[Molecular mechanisms of primary and secondary resistance, molecular-genetic features and characteristics of KIT/PDGFRA non-mutated GISTs].Semantic proximity Read ↗

Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour.Semantic proximity Read ↗

Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.Semantic proximity Read ↗

Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.Semantic proximity Read ↗

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.Semantic proximity Read ↗

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.